

Improving Safe Use of Hydromorphone in Electronic Medication Management (eMM) Systems

Rachael Worthington, Patient Safety and Clinical Benefits Lead, Clinical Engagement and Patient Safety¹
 Bayan Hosseini, Senior Improvement Lead, Medicines Critical Response and Governance²
¹ eHealth NSW ² Clinical Excellence Commission

Background

Hydromorphone is a potent opioid frequently used to treat moderate to severe, acute or chronic pain. Hydromorphone is 5 to 7 times more potent than morphine. Due to its high potency, errors with this medicine may result in serious adverse patient outcomes. Despite the release of three hydromorphone safety notices and alerts and the addition of a Hydromorphone Standard to the NSW Health High Risk Medicines Policy, serious hydromorphone incidents (including death) continue to occur without a decrease in frequency in NSW public hospitals. Although eMM has been shown to reduce medication errors, new safety risks can also be introduced associated with system use^{3,4} and monitoring of emerging safety risks can identify areas for improvement to mitigate risk and streamline clinician workflow⁴.

Objective

To review the prescribing of hydromorphone within public health facilities to inform state-wide recommended low dose order sentences for safer prescribing.

Methods

A working group was established to explore opportunities to improve hydromorphone prescribing. Proposed elements for low dose order sentences were considered following concerns around starting doses of hydromorphone (Figure 2). When presented for endorsement with relevant networks and expert advisory groups including palliative care and medication safety, conflicting feedback was received prompting a review of prescribing patterns for hydromorphone.

Serious incidents relating to hydromorphone were reviewed and a request sent to all local health districts (LHDs) and Specialty Health Networks (SHNs) to provide information on current prescribing practices over the period between February and April 2022. A list of order sentences built within the system were also received. The information was analysed and used to inform the decision around which low dose order sentences should be included as a state-based recommendation. All other order sentences for hydromorphone via subcutaneous injection were recommended to be removed from EMM systems.

Formulation	Dose	Route of administration	Frequency
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.25 mg	Subcutaneous injection	4 hourly (regular)
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.25 mg	Subcutaneous injection	4 hourly (if required), with maximum dose in 24 hours as a mandatory field

Figure 2: Initial Proposed Low Dose order Sentences



Figure 1: High Risk Medicines Management Policy

Policy Directive

High-Risk Medicines Management

Summary This Policy Directive outlines the requirements for the safe management and use of high-risk medicines.

Document type Policy Directive

Document number PD2020_045

Publication date 17 November 2020

Author branch Clinical Excellence Commission

Branch contact (02) 9229 5000

Review date 17 November 2023

Policy manual Not applicable

File number CEC 2020

Status Review

Functional group Clinical/Patient Services - Medical Treatment, Nursing and Midwifery, Pharmaceutical Corporate Administration - Governance, Records Population Health - Pharmaceutical

Applies to Local Health Districts, Board Governed Statutory Health Corporations, Specialty Network Governed Statutory Health Corporations, Community Health Centres, Public Hospitals

Distributed to Ministry of Health, Public Health System, Divisions of General Practice, Government Medical Officers, NSW Ambulance Service, Private Hospitals and Day Procedure Centres, Tertiary Education Institutes

Audience Clinical Administration/Medical Services/Nursing Staff/Pharmaceutical

Secretary, NSW Health
This Policy Directive may be varied, withdrawn or replaced at any time. Compliance with this directive is mandatory for NSW Health and is a condition of subsidy for public health organisations.




Figure 3: Consultation and Review Process to Define Low Dose Order Sentences

Results and Key Findings




Figure 4: Hydromorphone Doses Prescribed Across all Routes of administration.




Figure 5: Frequency of Hydromorphone 0.25mg Order Sentences Prescribed




Figure 6: Frequency of Hydromorphone 0.5mg Order Sentences Prescribed.




Figure 7: Number of Order Sentences Built in LHD/SHN Domain compared to unique order sentences seen in the extracts.

Formulation	Dose	Route of administration	Frequency
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.25 mg	Subcutaneous injection	2 hourly (if required), with maximum dose in 24 hours as a mandatory field
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.25 mg	Subcutaneous injection	4 hourly (if required), with maximum dose in 24 hours as a mandatory field
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.5 mg	Subcutaneous injection	2 hourly (if required), with maximum dose in 24 hours as a mandatory field
HYDROmorphone (dilaUDID) 2 mg/mL solution for injection	0.5 mg	Subcutaneous injection	4 hourly (if required), with maximum dose in 24 hours as a mandatory field

Figure 8: Number of Order Sentences Built in LHD/SHN Domain compared to unique order sentences seen in the extracts.

The prescribing data included 9342 unique order sentences, with 74% of orders via the subcutaneous route. On average each LHD had 28 order sentences pre-built in the system (Figure 7). Analysis demonstrated that the initial low dose orders sentences proposed would only account for 17% of current prescribing, but by representing the two most common doses and frequencies, this expanded to 41% of orders commonly prescribed. The amended proposal only includes PRN order sentences, prompting an active decision to prescribe regular doses, or amend an available order sentence if another dose or frequency is required.

Conclusion/Discussion

Of the serious incidents reviewed, 50% would be addressed by the creation of standardised low dose order sentences within the eMM system, with 50% occurring at the point of administration. This approach should also minimise the risk associated with prescribers amending field(s) to prescribe a dose or frequency outside of the available order sentences. Optimisation of eMM systems is an ongoing process and monitoring of the system to identify areas for system improvement, coupled with the use of real time eMM data and transparent reporting will maximise the benefits an electronic system can provide and improve patient care.

References:

1. NSW Health. (2020). PD2020_045. High Risk Medicines Management.
2. NSW Clinical Excellence Commission, (2020). Hydromorphone Standard Checklist.
3. Westbrook et al., (2013) JAMIA.
4. Kinlay et al., (2021) Appl Clin Inform.